Natera’s executive chairman sells $164,583 in stock

Matthew Rabinowitz, the Executive Chairman of Natera, Inc. (NASDAQ:NTRA), a company currently valued at $20.41 billion with its stock trading at $150.87, recently sold shares of the company’s stock, according to a filing with the Securities and Exchange Commission. The stock has shown remarkable performance, delivering a 62.4% return over the past year despite its characteristic volatility. On March 17, Rabinowitz sold a total of 1,127 shares of Natera’s common stock, with transaction prices ranging from $146.03 to $149.58 per share, amounting to a total sale value of $164,583.

Following these transactions, Rabinowitz retains direct ownership of 2,364,288 shares. Additionally, he holds an indirect interest in 84,000 shares through his spouse. The sales were conducted to meet tax withholding obligations related to the vesting of restricted stock units, as outlined in a pre-established trading plan compliant with Rule 10b5-1(c) under the Securities Exchange Act.

In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with a revenue of $476 million, marking a 53% increase year-over-year. The company also reported a narrower-than-expected loss per share of $0.41, which was better than the forecasted $0.49. Additionally, Natera’s gross margins improved significantly to 63%, up from 51% the previous year, and the company generated $46 million in cash flow during the quarter. Analysts at TD Cowen and Canaccord Genuity maintained their Buy ratings for Natera, with both firms setting a price target of $195, citing confidence in the company’s growth trajectory and financial health.

Moreover, Canaccord Genuity raised its price target from $180 to $195 following Natera’s strong fourth-quarter performance, which included significant growth in test volumes across its business segments. The firm’s analysts noted expectations of continued strong gross margins and positive cash flow, supported by potential benefits from improved Medicare Advantage rates and biomarker legislation. In other developments, Natera has initiated the HEROES clinical trial in France, aiming to explore the potential for reducing anti-HER2 targeted therapy in metastatic HER2+ breast cancer patients.

The trial, sponsored by Unicancer, will utilize Natera’s Signatera test to guide treatment de-escalation based on circulating tumor DNA (ctDNA) results. This study is expected to provide valuable insights into the feasibility of ctDNA-guided treatment strategies. Additionally, Natera’s recent guidance for 2025 has been well-received, with sales projections surpassing consensus estimates, further solidifying the company’s promising outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.